BrightSpring Health Services, Inc. — Cyborg Score 7/10
Strong
Home and Community-Based Healthcare Services
Strategic Profile
Leadership in specialty pharmacy and rare drug markets, along with exclusive launches, is fueling strong revenue growth and margin expansion. Sustained specialty pharmacy growth and a strong pipeline position the company for extended revenue and margin expansion, with operational excellence, tech-driven efficiency, and successful acquisition integration enhancing profit potential as industry shifts favor home and community care. The company agreed to sell its Community Living business, ResCare Community Living, to Sevita for $835 million in cash.
Cyborg Score Rationale
Revenue grew 27.65% to $11.27 billion in 2024 from $8.83 billion in 2023. According to 10 analysts, the average rating is "Strong Buy" with a 12-month price target of $41.67, representing 3.30% upside. However, the company posted negative TTM net income of -$20.5M and negative net profit margin of -0.18%, indicating profitability challenges despite strong revenue growth.
Top Insights
Specialty pharmacy growth and exclusive drug launches driving strong revenue expansion exceeding 27% YoY
Strategic divestiture of ResCare Community Living ($835M) signaling operational refocus on higher-margin pharmacy and clinical services
Serving 450,000+ customers across all 50 states in growing home and community-based care market driven by aging population
Analyst consensus bullish with 10-analyst "Strong Buy" rating, though company faces profitability improvements amid significant operating scale
Named Competitors
Waystar — Healthcare payments and revenue cycle management
Privia Health — Primary care and clinical services
HealthEquity — Healthcare financial services and HSA administration
Omnicell — Pharmacy automation and medication management
Recent Developments
(January 2025) Agreement to sell ResCare Community Living business to Sevita for $835 million
(2024) Revenue reached $11.27 billion, up 27.65% YoY; losses improved 88.32% to -$18.06 million
(February 2026) BrightSpring price target raised to $46 by TD Cowen and BMO Capital
Open the full interactive BrightSpring Health Services, Inc. report
Strategic research, analyst-debate audio, full Cyborg Score breakdown across 11 dimensions, and saved-company audio playlists.